Apx Acquisition CORP I

APX Acquisition Corp. I will be delisted from the Nasdaq Stock Market after failing to complete a business combination within the required timeframe.

APX Acquisition Corp. I has extended its deadline to complete a business combination to December 9, 2025, and modified redemption terms following shareholder approval at an extraordinary general meeting.

APX Acquisition Corp. I has entered into a promissory note agreement for $700,000 with Bioceres LLC, carrying a 20% annual interest rate, to fund working capital and business combination expenses.

APX Acquisition Corp. I has received notice that its warrants and units will be delisted from Nasdaq due to non-compliance with listing rules, while its Class A ordinary shares will remain listed.

APX Acquisition Corp. I received a notice from Nasdaq for failing to maintain the minimum market value for its outstanding warrants, putting them at risk of delisting.

APX Acquisition Corp. I has terminated its agreement to acquire MultiplAI Health Ltd due to financial and regulatory concerns, but will proceed with the merger with OmnigenicsAI Corp.

APx Acquisition Corp. I reported a significant net loss and increased liabilities for Q1 2025, raising substantial doubt about its ability to continue as a going concern following its delisting from Nasdaq and the termination of a key acquisition target.

APX Acquisition Corp. I announced a net income of $2.1 million for the third quarter of 2024, while navigating a proposed business combination and a notice of potential warrant delisting.

APX Acquisition Corp. I reports a net loss and working capital deficit in its latest 10-Q filing, raising concerns about its ability to continue as a going concern as it pursues a business combination.

APX Acquisition Corp. I reported a net loss of $2.25 million for the quarter ended March 31, 2024, and is working towards a business combination with OmnigenicsAI while facing uncertainties about its ability to continue as a going concern.

APx Acquisition Corp. I reports net income of $3.88 million for the three months ended September 30, 2023, and extends the deadline for completing a business combination.

APx Acquisition Corp. I's 10-K filing reveals ongoing efforts to complete a business combination with OmnigenicsAI, while navigating financial challenges, Nasdaq delisting, and material weaknesses in internal controls.

APx Acquisition Corp. I has filed its annual 10-K report, outlining its financial status, business activities, and plans for a proposed business combination.

CEO Kyle Bransfield reports a transfer of 100,000 Class A ordinary shares between Templar LLC and its subsidiary, Templar Subco LLC.

APX Acquisition Corp. I has entered into a definitive Business Combination Agreement with OmnigenicsAI Corp and MultiplAI Health Ltd to create a global AI-driven genomics platform, with OmnigenicsAI expected to be listed on Nasdaq under the ticker symbol OMNI.

CEO Kyle P. Bransfield reports the transfer of 800,000 Class A ordinary shares from Templar LLC to its wholly-owned subsidiary, Templar Subco LLC, on March 21, 2024.

APX Acquisition Corp. I is seeking shareholder approval to extend the deadline for completing a business combination to December 9, 2025, and to amend certain provisions in its governing documents.

First Trust Merger Arbitrage Fund and its affiliates have filed an amended Schedule 13G, indicating they no longer beneficially own any Class A Common Stock of APx Acquisition Corp. I as of December 31, 2024.

The Bank of New York Mellon Corporation has filed an amendment to its Schedule 13G, disclosing a passive beneficial ownership of 4.5% in APx Acquisition Corp. I's Class A Ordinary Shares as of January 15, 2025.

The Bank of New York Mellon Corporation has disclosed a passive 8.4% beneficial ownership stake in APx Acquisition Corp. I, holding 408,220 Class A Ordinary Shares.

Wolverine Asset Management LLC and its affiliated entities have filed an amended Schedule 13G, indicating they no longer hold any beneficial ownership in APx Acquisition Corp. I.